Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma
Juliet Wolford, Jiaru Bai, Kathleen N. Moore, Rebecca Kristeleit, Bradley J. Monk, Krishnansu S. Tewari
Topics & Concepts
MedicineOlaparibOncologyInternal medicineBRCA mutationBevacizumabChemotherapyProgression-free survivalCost effectivenessOvarian cancerCancerPoly ADP ribose polymeraseChemistryRisk analysis (engineering)GenePolymeraseBiochemistryPARP inhibition in cancer therapyAdvanced Breast Cancer TherapiesBRCA gene mutations in cancer